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Abstract
Background: Several lines of evidence suggest that the dopaminergic nervous system contributes to
methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between
dopamine and adenosine receptors. We therefore hypothesized that variations in the A2A adenosine receptor
(ADORA2A) gene modify genetic susceptibility to METH dependence/psychosis.
Methods: We first analyzed variations in the exons and exon-intron boundaries of the ADORA2A gene in METH
dependent/psychotic patients. Then an association analysis between these single nucleotide polymorphisms and
METH dependence/psychosis was performed using a total of 171 METH dependent/psychotic patients and 229
controls.
Results: We found 6 variations, of which one single nucleotide polymorphism (SNP) was novel. Significant
associations were observed between the allelic and genotypic frequencies of the Exon2+751 (rs5751876) SNP and
METH dependence/psychosis. These associations were observed especially in females. In the clinical feature
analyses, significant associations were observed between the SNP and the patient subgroup using METH alone (i.e.,
without concomitant use of other substances of abuse).
Conclusions: These results suggest that the ADORA2A gene could be a vulnerability factor for METH dependence/
psychosis, especially in females and/or in patients using only METH.
Background
Methamphetamine (METH) is a psychomotor stimulant
with high liability for abuse, and METH has become a
very serious social problem not only in Japan [1] but also
worldwide, including in the United States [2]. Use of
METH induces a strong psychological dependence, and
repeated usage frequently results in psychotic states, the
symptoms of which are similar to those of paranoid-type
schizophrenia [3,4]. Chronic METH abusers have been
shown to have persistent dopaminergic deficits [5,6].
Amphetamines are thought to produce their stimulant
effects mainly via the dopamine system [7,8], although
other systems may also be involved. Dopamine D1 and
D2 receptors exist as heterodimers with adenosine A1
and A2A receptors, respectively, which modulate their
responsiveness [9,10], suggesting that responses to
amphetamines may also be dependent on adenosinergic
function.
Several lines of evidence suggest that adenosine A2A
receptors (ADORA2A) play a role in inhibiting the effects
of METH. ADORA2A antagonists have been shown to
significantly increase the action of amphetamine-induced
locomotor activity in mice [11] and to mimic the discri-
minative-stimulus effects of METH in rats [12].
ADORA2A agonists reduced amphetamine-induced
locomotor activity in mice [11] and attenuated ampheta-
mine-induced stereotypy in rats [13]. ADORA2A gene
knockout mice showed attenuation in locomotor
responses [14] and no development of locomotor sensiti-
zation to amphetamine [15]. These reports suggest the
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agents to modulate adaptive responses to METH
exposure.
There have been no association analyses between
ADORA2A gene polymorphisms and METH depen-
dence/psychosis. In the present study, we analyzed all
coding exons and exon-intron boundaries of the
ADORA2A gene to reveal the variations in the Japanese
population and examined the associations between
novel and reported polymorphisms in the ADORA2A
gene and METH dependent/psychotic patients in Japan.
Methods
Subjects
One-hundred seventy-one unrelated patients with
METH dependence/psychosis (138 males and 33
females; mean age 37.5 ± 12.0 years) meeting ICD-10-
DCR criteria (F15.2 and F15.5) were used as case sub-
jects; they were outpatients or inpatients of psychiatric
hospitals. The 229 control subjects (119 males and 110
females; mean age 41.2 ± 12.3 years) were mostly medi-
cal staff members who had neither personal nor familial
history of drug dependence or psychotic disorders, as
verified by a clinical interview. All subjects were Japa-
nese, born and living in the northern Kyushu, Setouchi,
C h u k y o ,T o k a i ,a n dK a n t or e g i o n s .T h i ss t u d yw a s
approved by the ethical committees of each institute of
the Japanese Genetics Initiative for Drug Abuse
(JGIDA), and all subjects provided written informed
consent for the use of their DNA samples for this
research [3]. After informed consent was obtained,
blood samples were drawn and genomic DNA was
extracted by the phenol/chloroform method.
Defining variants of the ADORA2A gene
Initially, DNA samples from 16 METH dependent/
psychotic patients were used to identify nucleotide var-
iants within the ADORA2A gene (NCBI accession num-
bers: AP000355 and NT_011520). Exons 1, 2 and exon-
intron boundaries were amplified by polymerase chain
reaction (PCR) using a thermal cycler (Astec, Fukuoka,
Japan), and the products were sequenced in both direc-
tions using BigDye terminators (Applied Biosystems,
Foster City, CA) by an ABI Genetic analyzer 3100
(Applied Biosystems). The primers used for amplifying
exon 1 and its exon-intron boundaries were 1F and 4R,
and those used for sequencing were 1F, 1R, 2F, 2R, 3F,
3R, 4F, and 4R (Table 1). The primers used for amplify-
ing exon 2 and its exon-intron boundaries were 5F and
8 R ,a n dt h o s eu s e df o rs e q u e n c i n gw e r e5 F ,5 R ,6 F ,6 R ,
7F, 7R, 8F, and 8R.
Genotyping of both Exon1+179 (rs13306114) and
Exon1+219 was performed by PCR amplification using
3F and 4R primers followed by sequencing with 3F and
3R primers. Genotyping of IVS1+64 (rs13306116) was
performed by PCR amplification using 4F and 4R
primers followed by restriction enzyme BcnId i g e s t i o n
(PCR-restriction fragment length polymorphism; PCR-
RFLP). Genotyping of Exon2+751 (rs5751876) and IVS2
+28 (rs34923252) was performed by PCR amplification
using 5F and 8R primers followed by sequencing with
6F and 6R primers or 8F and 8R primers, respectively.
Clinical category analysis
For the clinical category analysis, the patients were
divided into two subgroups by four different clinical
features. As some subjects had missing data for some
clinical features, the sum of each subgroup was not total
to 171.
(A) Latency of psychosis from first METH intake: less
than 3 years (n = 64, average = 0.76y) or more than 3
years (n = 70, average = 9.4y). The course of METH
psychosis varied among patients, with some patients
showing psychosis sooner after the first METH intake,
as previously reported [3,16]. Because the median
latency was 3 years, this time point was used as the cut-
off in defining the two groups. (B) Duration of psychosis
after the last METH intake: transient (< 1 month) or
prolonged (≥ 1 month). Some patients showed continu-
ous psychotic symptoms even after METH discontinua-
tion, as previously reported [3,16]. Psychotic symptoms
disappeared in the patients with the transient-type
psychosis within one month after the discontinuation of
METH consumption and the beginning of treatment
with neuroleptics. Patients with the prolonged-type
psychosis had symptoms that continued for more than
one month even after the discontinuation of METH
consumption and the beginning of neuroleptic treat-
ment. (C) Spontaneous relapse: present or not. It has
been well documented that once METH psychosis has
developed, patients in the remission phase are liable to
spontaneous relapse without reconsumption [3,16]. (D)
Multiple drug usage: mono-drug (use of METH without
concomitant use of other drugs of abuse), or poly-drugs.
Some patients consumed multiple drugs in addition to
METH. They consumed at least either one of cocaine,
marihuana, morphine, heroin, LSD, alcohol or paint
thinner in addition to METH.
Statistical analysis
The Hardy-Weinberg (HW) equilibrium of genotypic
frequencies in each SNP was tested by the chi-square
test. The allelic and genotypic frequencies of patients
and control groups were compared using the chi-square
test. The level of statistical significance was set at a =
0.05. The odds ratio (OR) and its 95% confidence inter-
val (CI) were calculated as a measure of the association
between Exon2+751 (rs5751876) alleles and METH
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calculated by the Arlequin program available from
http://anthropologie.unige.ch/arlequin[17]. A global test
of differentiation among samples based on haplotype
frequencies was performed using the Arlequin program.
Results
Analysis of ADORA2A gene variants
To identify polymorphisms in the ADORA2A gene, all
coding exons and exon-intron boundaries were analyzed
using genomic DNA from 16 Japanese METH depen-
dent/psychotic subjects. Six single nucleotide poly-
morphisms (SNPs) were identified, of which one was
novel (Exon1+219) (Table 2). Consistent with the pre-
vious study in Japanese samples [18], we could not find
405C/T, 432C/T, or 1018C/T polymorphisms. Two
SNPs at Exon2+751 (rs5751876) and Exon2+1360
(rs35060421) were in linkage disequilibrium (LD) in the
sense that the genotypic patterns of the 16 samples
examined were the same. This LD has also been
reported in a Caucasian population [19]. We chose
Exon2+751 (rs5751876) to represent these SNPs.
Exon1+179 (rs13306114), Exon1+219, IVS1+64
(rs13306116), Exon2+751 (rs5751876) and IVS2+28
(rs34923252) were chosen for further analyses.
Relationship between ADORA2A gene SNPs and METH
dependence/psychosis
Association analyses between these SNPs in the
ADORA2A gene and METH dependence/psychosis were
performed using DNA samples from 171 METH depen-
dent/psychotic subjects and 229 control subjects. The
genotypic frequencies in these SNPs in controls were
within the Hardy-Weinberg expectations. Significant
differences were observed in both the genotypic (P =
0.018) and the allelic (P = 0.0057) frequencies of the
Exon2+751 (rs5751876) SNP between METH depen-
dent/psychotic patients and controls (Table 3). When
Bonferroni correction was performed according to the
number of SNPs examined, the corrected significance
level was p < 0.01 (0.05/5 = 0.1). Significance was still
observed in the allelic frequencies. Odds ratio of the
allelic frequencies of the Exon2+751 (rs5751876) SNP
between METH dependent/psychotic patients and con-
trols was 1.50 (95% CI: 1.13 to 1.99).
The SNPs having minor allele frequencies of over 5%,
Exon2+751 (rs5751876) and IVS2+28 (rs34923252),
were used for a global test of differentiation among sam-
ples based on haplotype frequencies using the Alrequin
program. Significant association with METH depen-
dence/psychosis was observed (P = 0.027).
Gender-dependent association analyses were per-
formed. In female samples, the Exon2+751 (rs5751876)
SNP showed significant associations with METH depen-
dence/psychosis in genotypic (P = 0.0078) and allelic
(P = 0.014) distributions (Table 4). When Bonferroni
correction was performed by gender (i.e., using two
categories: male or female), the corrected significance
level was P < 0.025. Female samples still showed
significance.
Subcategory analyses were performed on the clinical
parameters (latency of psychosis, prognosis psychosis,
spontaneous relapse, and multiple drug usage) on the
Exon2+751 (rs5751876) SNP (Table 5). Nominal
Table 1 Primers used in this study
Exon Forward Reverse
Exon 1 1F: GAGGTCCATTTGGATCCAGACCAT 1R: TTCTCTCGCCAGGCCAACTTCTCA
2F: ACATCCTTCCACATCCGAGCTCCA 2R: CAGGCCAGGTGTCAGCCTGAGGAT
3F: AGTCTCAGCGGGAATTCTATTGGA 3R: GACGAAGCAGGCAATGAAGAGGCA
4F: TACATCACGGTGGAGCTGGCCATT 4R: ACAGCTCCCTGCTAAGCCCAATGC
Exon 2 5F: ACTACTCAATGACCATCTGGGCAT 5R: TGATGGCCAGTGACTTGGCAGCAT
6F: TGCTGCTCATGCTGGGTGTCTATT 6R: TCTTCTCCCAACGTCACTGGTCAA
7F: TTAGCCATGAGCTCAAGGGAGTGT 7R: CTCTGGCACTGCTCTGTTACAACT
8F: TCACTCTCTGGCTGCTGGGTCTGC 8R: GTCACAGTTCTGAGAAGGTAACAT
Table 2 ADORA2A gene variants found in the Japanese population
Location Variants rs# Function Reference
Exon1+179 C/T rs13306114 untranslated
Exon1+219 C/T untranslated
IVS1+64 G/A rs13306116 intron
Exon2+751 C/T rs5751876 synonymous (Tyr- > Tyr) 1083C/T[30], 1976T/C[19]
Exon2+1360 T6/T7 rs35060421 untranslated 2592C/Tins[19]
IVS2+28 T/A rs34923252 intron
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prognosis of psychosis (P = 0.036), absence of sponta-
neous relapse (p = 0.046), and use of only METH
(P = 0.0099), when they were compared to controls.
When Bonferroni correction was performed according
to the number of subcategories (2), the corrected signifi-
cance level was p < 0.025. Significance was still observed
in the subjects using only METH. But these differences
were not observed between these patient subgroups.
Discussion
We analyzed ADORA2A gene variations in a Japanese
population and found six SNPs in exons and exon-
intron boundaries. Significant associations were
observed between the Exon2+751 (rs5751876) SNP and
METH dependence/psychosis. The Exon2+751
(rs5751876) SNP showed significant associations with
METH dependence/psychosis in female samples and
with subjects using only METH.
This is the first report of an association analysis
between ADORA2A gene polymorphisms and METH
dependence/psychosis. The result that METH depen-
dence/psychosis was significantly associated with
ADORA2A gene polymorphism was in line with the
findings in animal studies. In animals, the pharmacologi-
cal effects of psychostimulants like cocaine and amphe-
tamine were counteracted by ADORA2A agonists and
potentiated by ADORA2A antagonists [20-23].
Exon2+751 (rs5751876) SNP showed a significant asso-
ciation with METH dependence/psychosis. As Exon2+751
(rs5751876) SNP is a synonymous variant, this SNP can-
not include amino acid substitutions. However, we found
one untranslated region SNP, Exon2+1360 (rs35060421,
2592C/Tins [19]), in LD with Exon2+751 (rs5751876).
This LD was also reported in a Caucasian population [19].
While there is no evidence of functional alterations of
these SNPs at this time point, one may hypothesize that
untranslated region SNPs would change gene expression
Table 3 Genotype and allele frequencies of the ADORA2A gene SNPs in patients and controls
SNP Group N Genotype (%) P Allele (%) P
Exon1+179 (rs13306114) C/C C/C C/T T/T C T
Control 229 229 (100.0%) 0 (0.0%) 0 (0.0%) 458 (100.0%) 0 (0.0%)
METH 171 168 (98.2%) 3 (1.8%) 0 (0.0%) 0.132 339 (99.1%) 3 (0.9%) 0.154
Exon1+219 C/C C/T T/T C T
Control 229 228 (99.6%) 1 (0.4%) 0 (0.0%) 457 (99.8%) 1 (0.2%)
METH 171 169 (98.8%) 2 (1.2%) 0 (0.0%) 0.701 340 (99.4%) 2 (0.6%) 0.807
IVS1+64 (rs13306116) G/G G/A A/A G A
Control 229 219 (95.6%) 10 (4.4%) 0 (0.0%) 448 (97.8%) 10 (2.2%)
METH*
1 171 162 (94.7%) 8 (4.7%) 1 (0.6%) 0.504 332 (97.1%) 10 (2.9%) 0.663
Exon2+751 (rs5751876) T/T T/C C/C T C
Control 229 70 (30.6%) 114 (49.8%) 45 (19.7%) 254 (55.5%) 204 (44.5%)
METH 171 35 (20.5%) 85 (49.7%) 51 (29.8%) 0.018 155 (45.3%) 187 (54.7%) 0.0057
IVS2+28 (rs34923252) T/T T/A A/A T A
Control 229 181 (79.0%) 43 (18.8%) 5 (2.2%) 405 (88.4%) 53 (11.6%)
METH 171 144 (84.2%) 26 (15.2%) 1 (0.6%) 0.258 314 (91.8%) 28 (8.2%) 0.146
*1: METH sample: Hardy-Weinberg Equilibrium p = 0.0214
N: Number of samples
P: Significance values between METH samples and controls.
Table 4 Gender-dependent association analyses of the Exon2+751 (rs5751876) SNP in patients and controls
Gender Group N Genotype (%) P Allele (%) P
Male
T/T T/C C/C T C
Control 119 31 (26.1%) 59 (49.6%) 29 (24.4%) 121 (50.8%) 117 (49.2%)
METH 138 27 (19.6%) 73 (52.9%) 38 (27.5%) 0.456 127 (46.0%) 149 (54.0%) 0.315
Female
T/T T/C C/C T C
Control 110 39 (35.5%) 55 (50.0%) 16 (14.5%) 133 (60.5%) 87 (39.5%)
METH 33 8 (24.2%) 12 (36.4%) 13 (39.4%) 0.0078 28 (42.4%) 38 (57.6%) 0.014
N: Number of samples
P: Significance values between METH samples and controls.
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the pathophysiology of METH dependence/psychosis.
Further analyses are necessary to study the functions of
these SNPs or other SNPs in LD.
Significant difference was observed between the sub-
group of patients using only METH and the controls in
the variation of Exon2+751 (rs5751876) SNP, while no
difference was observed between the subgroup of
patients using poly-drugs and the controls nor within
patient subgroups. The reason why the significant asso-
ciation was observed only in the patient subgroup using
exclusively METH compared to controls is not known;
however, further analyses in this patient subgroup could
reveal the reasons for their predilection for METH
alone. Actually, an association has been reported
between the ADORA2A variants in the 1976C/T (Exon2
+751) and 2592C/T(ins) (Exon2+1360) polymorphisms
and the anxiogenic response to amphetamine in healthy
subjects [24]. Hohoff and colleagues found that its effect
on anxiety was stronger at the lower amphetamine dose
and discussed that relatively small genetic effects are
more relevant at lower doses of amphetamine and can
be overcome by increasing the amphetamine dose [24].
Emotional alterations and/or the dose of METH use
might be mediated by these SNPs and that will likely be
one of the key to understanding METH dependence/
psychosis.
We found a significant association between the female
subjects with METH dependence/psychosis and Exon2
+751 (rs5751876) SNP. These gender different associa-
tions between METH dependence/psychosis and SNPs
have also been reported in several genes [25-28]. It has
well been known and studied that male and female
differ markedly with regard to their use of, and
responses to, METH and related amphetamines [29].
Dluzen and colleagues summarized the data from pub-
lished articles on gender differences in various para-
meters of METH use and responses and concluded that
women seemed more dependent on and committed to
METH but showed diminished (amphetamine-stimu-
lated) dopamine responses and a decreased degree of
toxicity [29]. Although larger replication studies need to
be conducted on the association analysis between the
SNP and METH dependence/psychosis in females, our
results offer a potential means for understanding the dif-
ferences between female and male in the progression to
METH dependence/psychosis.
Limitations
The limitation of our study is its moderate sample size,
especially in gender-dependent association analyses and
in clinical category analyses. Although the number of
our study subjects is generally regarded as small for
association studies, it is hard to obtain many patient
samples due to the illegality of METH use in Japan. We
therefore organized the Japanese Genetics Initiative for
Drug Abuse (JGIDA) to collect samples. Based on these
efforts, we could finally obtain this moderate number of
patient samples. Nevertheless, our study needs to be
reproduced in a larger sample size regarding the associa-
tions between these SNPs and METH dependence/
psychosis.
Conclusions
Our results suggest that the ADORA2A gene could be a
vulnerability factor for METH dependence/psychosis,
Table 5 Association analyses between the Exon2+751 (rs5751876) SNP and clinically subcategorized METH subjects
Samples Subgroups N Genotype (%) P1 P2
T T/C C
Control 229 70 (31%) 114 (50%) 45 (20%)
METH Latency of Psychosis
< 3 years 64 15 (23%) 32 (50%) 17 (27%) 0.366
≥ 3 years 70 17 (24%) 30 (43%) 23 (33%) 0.068 0.663
Prognosis of Psychosis
Transient (< 1 month) 91 21 (23%) 40 (44%) 30 (33%) 0.036
Prolonged (≥ 1 month) 56 11 (20%) 34 (61%) 11 (20%) 0.231 0.115
Spontaneous Relapse
Not present 104 22 (21%) 50 (48%) 32 (31%) 0.046
Present 60 12 (20%) 31 (52%) 17 (28%) 0.167 0.905
Multiple Drug Usage
None (METH use only) 52 6 (12%) 29 (56%) 17 (33%) 0.0099
Poly-drugs 112 26 (23%) 54 (48%) 32 (29%) 0.127 0.214
N: Number of samples
P1: Significance values between METH samples and controls.
P2: Significance values between the subgroups in each clinical category
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METH. Further investigations of the role of the
ADORA2A gene in the development of METH depen-
dence/psychosis are warranted.
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